(Q45192232)

10 December 2017

title

Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients (English)

1 reference

10 December 2017

0 references

1 reference

A Chan

1

1 reference

10 December 2017

F X Weilbach

series ordinal

2

1 reference

10 December 2017

K V Toyka

series ordinal

3

1 reference

10 December 2017

R Gold

series ordinal

4

1 reference

10 December 2017

publication date

1 January 2005

1 reference

Clinical and Experimental Immunology

10 December 2017

published in

1 reference

10 December 2017

volume

139

1 reference

10 December 2017

issue

1

1 reference

10 December 2017

page(s)

152-158

1 reference

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2005.02653.X

Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG]

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2005.02653.X

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2005.02653.X

High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2005.02653.X

A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2005.02653.X

A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2005.02653.X

T-cell apoptosis in autoimmune diseases: termination of inflammation in the nervous system and other sites with specialized immune-defense mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2249.2005.02653.X

Phagocytosis of apoptotic inflammatory cells by microglia and its therapeutic implications: termination of CNS autoimmune inflammation and modulation by interferon-beta

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1809264

Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event

27 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1809264

Effects of mitoxantrone on multiple sclerosis patients' lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10.

27 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1809264

New concepts in the immunopathogenesis of multiple sclerosis

27 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1809264

Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders

27 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1809264

Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells.

27 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1809264

High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells

27 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1809264

Mitoxantrone (novantrone): a review of experimental and early clinical studies

27 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1809264

Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice.

27 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1809264

Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foci of rats.

27 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1809264

Treatment of multiple sclerosis with mitoxantrone

27 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1809264

T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy

27 August 2018

1 reference

12 December 2020

Mitoxantrone affects topoisomerase activities in human breast cancer cells

1 reference

12 December 2020

Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function

1 reference

12 December 2020

Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells

1 reference

12 December 2020

10.1111/J.1365-2249.2005.02653.X

Identifiers

DOI

1 reference

10 December 2017

0 references

1 reference